About
Technology
Issues
FAQ
Links
Official Page
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.